CD274 and cancer: For example, increasing evidence demonstrated that targeting ubiquitination of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) could be a promising therapeutic approach for cancer immunotherapy (Hu et al., 2021).